BioNxt Solutions Reports Significant Preclinical Advance for MS Treatment

BioNxt Solutions Inc. has announced a key preclinical milestone for its experimental multiple sclerosis therapy. The Canadian biotechnology firm’s innovative oral film formulation demonstrated a substantial improvement in drug delivery compared to standard tablets in a recent study, paving the way for upcoming human clinical trials.

Strategic Focus and Market Context

The company’s strategy centers on reformulating established or advanced drug compounds using its proprietary delivery platform, rather than discovering new molecules. This approach has the potential to streamline regulatory pathways. The initial target is the global multiple sclerosis market, where comparable cladribine-based therapies like Mavenclad generate annual revenues exceeding $1.2 billion, a segment experiencing consistent double-digit growth.

BioNxt’s needle-free, swallow-free sublingual application could offer distinct advantages for patients with neurological or neuromuscular limitations, potentially improving treatment accessibility and adherence.

Study Details Reveal Clear Pharmacokinetic Edge

A completed preclinical study using mature minipigs (40-50 kg)—an established pharmacological model known for its strong similarity to human oral and mucosal drug absorption—confirmed the superiority of BioNxt’s sublingual delivery method. The orally dissolving film (ODF), placed under the tongue, achieved a measurably higher systemic availability of the MS drug Cladribine over a 48-hour period.

Should investors sell immediately? Or is it worth buying Bionxt Solutions?

Key pharmacokinetic data from the study includes:
* Sublingual ODF average AUC (0-48h): 39.46 ng·h/mL
* Conventional tablet average AUC (0-48h): 28.11 ng·h/mL
* Result: An approximate 40% higher concentration of the active drug in the body.

Path Forward: Clinical Development and Platform Potential

With these results in hand, BioNxt is preparing to advance into human pharmacokinetic and bioequivalence studies. Concurrent activities include initiating GMP-compliant manufacturing and completing regulatory groundwork. CEO Hugh Rogers described the findings as providing a “robust scientific foundation” for this next phase of development.

The company is positioning its sublingual ODF technology as a scalable platform with applications beyond multiple sclerosis. It has identified Myasthenia Gravis, an autoimmune disorder where patients frequently experience swallowing difficulties, as another potential indication for the delivery system.

BioNxt Solutions, with 122.5 million shares outstanding, last traded at $0.36 on the OTCQB market. Throughout 2025, its share price has fluctuated between $0.22 and $0.80. The forthcoming human clinical trials will be critical in determining whether the promising preclinical data translates effectively to patient treatment.